UNSPSC 51383502: Delmetacin

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C18H15NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I9Q51XHI1K, chemically known as 1h-indole-3-acetic acid, 1-benzoyl-2-methyl- (9ci) but generally known as delmetacin, which bears US NIH Compound Identifier 27860. European Medicines Agency schedules Delmetacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06955MIG. The term DELMETACIN is an International Non-Proprietary Name.

UNSPSC 51383502 Delmetacin is a Commodity code that in practice captures state and local procurement of naloxone, drug deactivation systems, generic pharmaceuticals, and over-the-counter products supplied through authorized wholesalers or direct manufacturer relationships. State and local governments are buying emergency opioid-reversal medications, harm-reduction equipment, and pharmaceutical inventory for community health programs, corrections facilities, and employee health benefit plans. Issuing bodies include county health departments, state health and human services agencies, and cooperative purchasing alliances spanning multiple jurisdictions. The scope ranges from tactical annual purchases of specific units (naloxone and deactivation systems for a single county) to strategic market research and contracting infrastructure for statewide or multistate pharmacy benefit programs serving dozens of participating agencies.

Activity is concentrated in the Southeast and Upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling intention to shift procurement away from pharmacy benefit managers toward direct manufacturer contracts. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 with a March 26, 2026 response deadline to establish multiple contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), with awarded vendors effective July 1, 2026 and serving participating agencies in Minnesota, Oregon, and other states. Vendors pursuing this code should expect to meet cGMP certification, Drug Supply Chain Security Act compliance, and substantial insurance requirements ($5 million commercial general liability minimum in the MMCAP RFP), with pricing evaluated heavily on competitiveness and compliance with administrative data standards.